Compare Biocon with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs DIVIS LABORATORIES - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON DIVIS LABORATORIES BIOCON /
DIVIS LABORATORIES
 
P/E (TTM) x 31.8 58.0 54.9% View Chart
P/BV x 3.8 15.5 24.4% View Chart
Dividend Yield % 0.3 0.4 65.9%  

Financials

 BIOCON    DIVIS LABORATORIES
EQUITY SHARE DATA
    BIOCON
Mar-19
DIVIS LABORATORIES
Mar-19
BIOCON /
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs7071,639 43.1%   
Low Rs5541,115 49.7%   
Sales per share (Unadj.) Rs91.9186.3 49.3%  
Earnings per share (Unadj.) Rs16.751.0 32.8%  
Cash flow per share (Unadj.) Rs24.257.3 42.2%  
Dividends per share (Unadj.) Rs1.0016.00 6.3%  
Dividend yield (eoy) %0.21.2 13.7%  
Book value per share (Unadj.) Rs101.6261.8 38.8%  
Shares outstanding (eoy) m600.00265.47 226.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.97.4 92.8%   
Avg P/E ratio x37.727.0 139.6%  
P/CF ratio (eoy) x26.124.0 108.6%  
Price / Book Value ratio x6.25.3 117.9%  
Dividend payout %6.031.4 19.1%   
Avg Mkt Cap Rs m378,330365,592 103.5%   
No. of employees `0006.111.8 51.8%   
Total wages/salary Rs m11,6535,423 214.9%   
Avg. sales/employee Rs Th8,994.34,175.1 215.4%   
Avg. wages/employee Rs Th1,900.7457.7 415.2%   
Avg. net profit/employee Rs Th1,635.31,141.8 143.2%   
INCOME DATA
Net Sales Rs m55,14449,463 111.5%  
Other income Rs m1,4441,556 92.8%   
Total revenues Rs m56,58851,019 110.9%   
Gross profit Rs m15,88318,718 84.9%  
Depreciation Rs m4,4781,689 265.1%   
Interest Rs m70935 2,025.7%   
Profit before tax Rs m12,14018,551 65.4%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1235,023 42.3%   
Profit after tax Rs m10,02613,527 74.1%  
Gross profit margin %28.837.8 76.1%  
Effective tax rate %17.527.1 64.6%   
Net profit margin %18.227.3 66.5%  
BALANCE SHEET DATA
Current assets Rs m48,22846,501 103.7%   
Current liabilities Rs m30,3768,468 358.7%   
Net working cap to sales %32.476.9 42.1%  
Current ratio x1.65.5 28.9%  
Inventory Days Days68131 52.2%  
Debtors Days Days8686 99.6%  
Net fixed assets Rs m64,13025,797 248.6%   
Share capital Rs m3,000531 565.1%   
"Free" reserves Rs m57,98068,962 84.1%   
Net worth Rs m60,98069,493 87.7%   
Long term debt Rs m15,7660-   
Total assets Rs m121,92480,383 151.7%  
Interest coverage x18.1531.0 3.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.6 73.5%   
Return on assets %8.816.9 52.2%  
Return on equity %16.419.5 84.5%  
Return on capital %16.826.7 62.6%  
Exports to sales %28.10-   
Imports to sales %18.924.6 76.5%   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,39912,187 85.3%   
Fx inflow Rs m15,50641,238 37.6%   
Fx outflow Rs m10,39912,405 83.8%   
Net fx Rs m5,10728,833 17.7%   
CASH FLOW
From Operations Rs m11,5469,543 121.0%  
From Investments Rs m-7,138-6,854 104.1%  
From Financial Activity Rs m-2,417-2,459 98.3%  
Net Cashflow Rs m2,103230 915.9%  

Share Holding

Indian Promoters % 40.4 52.0 77.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 11.8 71.2%  
FIIs % 10.7 19.0 56.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.2 115.7%  
Shareholders   109,995 31,796 345.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT PHARMOVA   

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 12, 2021 (Close)

TRACK BIOCON

BIOCON - AUROBINDO PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS